Get the Stockscreener App
101.35
3.48%
-3.65
After Hours:
102.00
0.65
+0.64%
Insmed Inc stock is traded at $101.35, with a volume of 8.59M.
It is down -3.48% in the last 24 hours and down -36.73% over the past month.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
See More
Previous Close:
$105.00
Open:
$108.01
24h Volume:
8.59M
Relative Volume:
3.46
Market Cap:
$21.97B
Revenue:
$606.42M
Net Income/Loss:
$-1.28B
P/E Ratio:
-15.83
EPS:
-6.403
Net Cash Flow:
$-997.58M
1W Performance:
-23.95%
1M Performance:
-36.73%
6M Performance:
-46.57%
1Y Performance:
+54.43%
1-Day Range:
$98.98
$108.63
1-Week Range:
$98.98
$142.90
52-Week Range:
$64.84
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
101.35 | 21.97B | 606.42M | -1.28B | -997.58M | -6.403 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Mar-30-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $160 to $237 - Moomoo
Insmed Incorporated (NASDAQ:INSM) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Moomoo
Here's What Analysts Are Forecasting For Insmed Incorporated (NASDAQ:INSM) After Its First-Quarter Results - Yahoo Finance Singapore
Insmed (INSM) Q1 2026 Revenue Surge Tests Profitability Narrative - simplywall.st
Insmed (INSM) Post-Earnings Selloff Seen as Buying Opportunity - GuruFocus
INSM Maintained by RBC Capital -- Price Target Lowered to $205 - GuruFocus
INSM Maintained by Wells Fargo -- Price Target Lowered to $160 - GuruFocus
Insmed Stock Sell-off Is Overdone as Underlying Metrics Appear Positive, RBC Says - Moomoo
Insmed Stock Sell-off is Overdone as Underlying Metrics Appear Positive, RBC Says - marketscreener.com
RBC Cuts Price Target on Insmed to $205 From $220, Keeps Outperform Rating - marketscreener.com
Insmed's Q1 earnings beat, sales miss estimates, stock tanks 23% - MSN
INSM Maintains by Guggenheim -- Price Target Lowered to $226 - GuruFocus
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $160 to $243 - Moomoo
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23% - TradingView
Insmed’s 44% decline validates InvestingPro’s overvalued call By Investing.com - Investing.com
Insmed Q1 Earnings Call Highlights - Yahoo Finance
TD Cowen Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $243 - Moomoo
Insmed Earnings Call Highlights BRINSUPRI-Driven Momentum - TipRanks
Insmed's Blockbuster Drug Brinsupri Drives Record Revenue, Yet Shares Tumble - AD HOC NEWS
Insmed (INSM) Q1 2026 Earnings Transcript - The Globe and Mail
Roth MKM Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $212 - Moomoo
Insmed Incorporated Q1 2026 Earnings Call Summary - Yahoo Finance
Insmed Bronchiectasis Push With Ty Pennington May Expand Therapy Opportunity - simplywall.st
U.S. Indexes Closed Down Thursday; Insmed Fell Furthest - Barron's
Insmed reiterates BRINSUPRI at least $1B 2026 revenue target while targeting ARIKAYCE label expansion in H1 2027 - MSN
Biotech Tanks On Its Biggest Launch; Why Analysts Are Bullish - Investor's Business Daily
Insmed Down Over 21%, Worst Performer in the Nasdaq 100 So Far Today -- Data Talk - Moomoo
Insmed Q1 2026 slides: BRINSUPRI surges 44%, ARIKAYCE expansion ahead - Investing.com
Earnings call transcript: Insmed Q1 2026 beats forecasts but stock tumbles - Investing.com
Nasdaq 100 Climbs Records, Oil Extends Drop As Iran Weighs Hormuz Deal: Stock Market Today - Benzinga
Earnings call transcript: Insmed Q1 2026 beats forecasts but stock tumbles By Investing.com - Investing.com South Africa
William Blair Maintains Insmed(INSM.US) With Buy Rating - Moomoo
IBD: Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish - Moomoo
INSM: BRINSUPRI's launch outperformed expectations, driving strong revenue and sustained growth - TradingView
Why is Insmed stock sliding today? - Investing.com
Why is Insmed stock sliding today? By Investing.com - Investing.com Canada
Insmed Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Insmed Inc Stock Warning Signs - GuruFocus
Insmed Q1 Loss Narrows, Revenue Rises; Shares Down Pre-Bell - Moomoo
Insmed reports new cathepsin C inhibitors - BioWorld News
Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Insmed (NASDAQ:INSM) Q1 Revenue Miss Triggers Pre-Market Slide Despite Narrower Loss - ChartMill
Insmed stock falls 6% on Q1 beat as investors eye guidance By Investing.com - Investing.com UK
Q1 2026 Insmed Inc Earnings Call Transcript - GuruFocus
Earnings Flash (INSM) Insmed Incorporated Reports Q1 Revenue $306.0M, vs. FactSet Est of $300.8M - marketscreener.com
Earnings Flash (INSM) Insmed Posts Q1 Net Product Revenue $306M, vs. FactSet Est of $300.8M - marketscreener.com
Earnings Flash (INSM) Insmed Posts Q1 Loss $0.76 a Share, vs. FactSet Est of $0.96 Loss - marketscreener.com
INSMED ($INSM) Releases Q1 2026 Earnings - Quiver Quantitative
Insmed: Q1 Earnings Snapshot - marketscreener.com
Insmed Q1 revenue jumps 230%, net loss narrows - TradingView
INSMED Inc 1Q 2026: Revenue $306M, EPS $(0.76) — 10-Q Summary - TradingView
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.97%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):